ACCP on cough
This article was originally published in The Tan Sheet
Executive Summary
The American College of Chest Physicians "uses the most rigorous and current methods to develop its evidence-based clinical practice guidelines, including those for cough," Richard Irwin, Chairman of ACCP's Cough Guidelines Committee, et al., state in a letter to The Lancet March 25. The group responds to a January editorial, which said ACCP cough treatment guidelines "may be a hollow exercise." ACCP said there was no evidence that OTC expectorants or suppressants relieve cough (1"The Tan Sheet" Jan. 16, 2006, p. 4). According to The Lancet, over half of the guidelines are "based more on opinion that on evidence," and one third are "based on 'low' evidence, yet backed with the second highest grade (B) of support." In response, Irwin et al. assert that the guide is "based on the best available evidence" and that when evidence was not robust, "the panel had to decide whether to do nothing or to offer some guidance to clinicians faced with patients in need of medical management." Where no published clinical trial results existed, panel members provided guidance and guidelines were graded with an "E" for "expert" in order to be "totally transparent," Irwin et al. say...
You may also be interested in...
Most OTC Cough Meds Dismissed By Chest Physicians Guidelines
The only effective OTC treatments for acute cough due to the common cold are older antihistamine/ decongestant products such as Wyeth's Dimetapp, according to revised guidelines issued by the American College of Chest Physicians
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.